This week the Cancer Conference Coverage moves to the joint IASLC-AACR symposium on the Molecular Origins of Lung Cancer in San Diego.  Having attended previous events (this is the third one they’ve hosted) and rather enjoyed them, this year I’m following it remotely.

What’s particularly nice about this type of specialist event is that they are especially useful for chatting informally with attendees and being able to ask a lot of questions that simply wouldn’t be feasible at larger meetings due to time and other constraints.

This review covers my thoughts on two immunotherapies, namely Merck’s anti-PD-1, which was previously presented at the World Lung Conference, plus a completely novel and very different approach that looks really quite exciting.

You can sign in or sign up below to read more tangible details.

Posted by 

Purchase Access to Premium Content

Click on blue icon to purchase a PERSONAL, INDIVIDUAL license to premium content. You are NOT PERMITTED to share access or copies of posts. If you wish to purchase a CORPORATE or MULTI-USER license or want to be able to share content PLEASE CONTACT US to purchase this. Please read the terms of use before purchasing & if you work in PR, Communications or for an agency, the guidance within it. Rates may change without notice and are non-refundable.